Metastatic prostate cancer with low PSA levels diagnosed after holmium laser enucleation of the prostate
Tóm tắt
Holmium laser enucleation of the prostate is a widely accepted surgical treatment method for benign prostate hyperplasia, but its effect on prostate cancer remains unclear. In this study, we report the cases of two patients with metastatic prostate cancer diagnosed during follow-up after holmium laser enucleation of the prostate. Case 1 was a 74 year-old man who underwent holmium laser enucleation of the prostate. Prostate-specific antigen levels declined from 4.3 to 1.5 ng/mL at 1 month after surgery, but after 19 months, they increased to 6.6 ng/mL. Based on pathological and radiological findings, he was diagnosed as having prostate cancer, with Gleason score 5 + 4 with neuroendocrine differentiation, cT3bN1M1a. Case 2 was a 70 year-old man who also underwent holmium laser enucleation of the prostate. Prostate-specific antigen levels declined from 7.2 to 2.9 ng/mL at 6 months after surgery, but after 12 months, they increased to 12 ng/mL. Based on pathological and radiological findings, he was diagnosed as having prostate cancer, with Gleason score 4 + 5 with intraductal carcinoma of the prostate, cT3bN1M1a. This report suggests that advanced prostate cancer may be newly diagnosed after holmium laser enucleation of the prostate. Even if prostate cancer had not been demonstrated in the enucleated specimen, and postoperative PSA levels were below the standard values, physicians should regularly monitor prostate-specific antigen levels after holmium laser enucleation of the prostate, and further examination should be considered keeping in mind prostate cancer progression.
Tài liệu tham khảo
Krambeck AE, Handa SE, Lingeman JE (2013) Experience with more than 1,000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol 189:S141-145. https://doi.org/10.1016/j.juro.2012.11.027
Hanks GE, Leibel S, Kramer S (1983) The dissemination of cancer by transurethral resection of locally advanced prostate cancer. J Urol 129:309–311. https://doi.org/10.1016/s0022-5347(17)52069-8
Krupski TL, Stukenborg GJ, Moon K et al (2010) The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU Int 106:1477–1483. https://doi.org/10.1111/j.1464-410X.2010.09356.x
Kida K, Shimizu Y, Ogawa K et al (2018) A case of rapidly progressing prostate cancer diagnosed 20 months after holmium laser enucleation of the prostate. Int Cancer Conf J 7:81–83. https://doi.org/10.1007/s13691-018-0324-3
Koguchi D, Nishi M, Satoh T et al (2014) Bone dissemination of prostate cancer after holmium laser enucleation of the prostate: a case report and a review of the literature. Int J Urol 21:215–217. https://doi.org/10.1111/iju.12248
Abedali ZA, Calaway AC, Large T et al (2020) The Role of prostate specific antigen monitoring after holmium laser enucleation of the prostate. J Urol 203:304–310. https://doi.org/10.1097/ju.0000000000000530
Nakamura Y, Taguchi S, Masuda K et al (2020) Assessment of incidental prostate cancer in HoLEP specimens and newly-diagnosed prostate cancer after HoLEP. Japanese J Endourol 33:335–340. https://doi.org/10.11302/jsejje.33.335
Elmansy HM, Elzayat EA, Sampalis JS et al (2009) Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy. Urology 74:1105–1110. https://doi.org/10.1016/j.urology.2009.06.039
Heung YM, Walsh K, Sriprasad S et al (2000) The detection of prostate cells by the reverse transcription-polymerase chain reaction in the circulation of patients undergoing transurethral resection of the prostate. BJU Int 85:65–69. https://doi.org/10.1046/j.1464-410x.2000.00380.x